Literature DB >> 2984709

Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms.

T Mennini, S Garattini, S Caccia.   

Abstract

A study of the possible molecular mechanisms of action by which the isomers and metabolites of fenfluramine increase serotonin transmission, leading to anorectic activity, is presented. The actual brain levels of fenfluramine and norfenfluramine isomers after administration of equi-anorectic doses to rats are compared with their potencies in affecting serotonergic mechanisms in vitro. Isomers and metabolites of fenfluramine can have the same pharmacological action by influencing serotonin uptake, release and binding in a quantitatively different manner.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984709     DOI: 10.1007/bf00427333

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Evidence of the existence of two different intraneuronal pools from which pharmacological agents can release serotonin.

Authors:  T Mennini; E Borroni; R Samanin; S Garattini
Journal:  Neurochem Int       Date:  1981       Impact factor: 3.921

2.  Gas-liquid chromatographic determination of the optical isomers of fenfluramine and norfenfluramine in biological samples.

Authors:  S Caccia; A Jori
Journal:  J Chromatogr       Date:  1977-11-21

3.  Effects of narcotic analgesics on the uptake and release of 5-hydroxytryptamine in rat synaptosomal preparations.

Authors:  T Mennini; R Pataccini; R Samanin
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

4.  Localization of fenfluramine and reserpine in brain regions of rats with extensive degeneration of 5-hydroxytryptaminergic neurons.

Authors:  T Mennini; R Pataccini; V Crunelli; S Caccia; M Ballabio; R Samanin; S Garattini
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

5.  Evidence that it is possible to cause anorexia by increasing release and/or directly stimulating postsynaptic serotonin receptors in the brain.

Authors:  R Samanin; T Mennini; S Garattini
Journal:  Prog Neuropsychopharmacol       Date:  1980

6.  Stereoselective disposition of fenfluramine enantiomers in the rat.

Authors:  A Jori; P De Ponte; S Caccia
Journal:  Xenobiotica       Date:  1978-09       Impact factor: 1.908

7.  Differences between d-fenfluramine and d-norfenfluramine in serotonin presynaptic mechanisms.

Authors:  E Borroni; A Ceci; S Garattini; T Mennini
Journal:  J Neurochem       Date:  1983-03       Impact factor: 5.372

8.  Is receptor activation involved in the mechanism by which (+)-fenfluramine and (+)-norfenfluramine deplete 5-hydroxytryptamine in the rat brain?

Authors:  R Invernizzi; K Kmieciak-Kolada; R Samanin
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

9.  Pharmacokinetics of fenfluramine enantiomers in man.

Authors:  S Caccia; M Ballabio; P De Ponte
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

10.  Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats.

Authors:  R Samanin; T Mennini; A Ferraris; C Bendotti; F Borsini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

View more
  13 in total

1.  Acute and chronic D-fenfluramine treatments have different effects on serotonin synthesis rates in the rat brain: an autoradiographic study.

Authors:  F Yamane; Y Tohyama; M Diksic
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 2.  Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.

Authors:  S Garattini
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 3.  Labelled alpha-methyl-L-tryptophan as a tracer for the study of the brain serotonergic system.

Authors:  M Diksic
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

4.  Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype.

Authors:  S P Vickers; P G Clifton; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

5.  Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release.

Authors:  C W Callaway; L L Wing; D E Nichols; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.

Authors:  T Mennini; A Bizzi; S Caccia; A Codegoni; C Fracasso; E Frittoli; G Guiso; I M Padura; C Taddei; A Uslenghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

7.  Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin.

Authors:  M Gobbi; E Frittoli; T Mennini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

8.  Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms.

Authors:  S Caccia; M Anelli; C Fracasso; E Frittoli; P Giorcelli; M Gobbi; C Taddei; S Garattini; T Mennini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

9.  Effect of hypothalamic and peripheral fluoxetine injection on natural patterns of macronutrient intake in the rat.

Authors:  G F Weiss; N Rogacki; A Fueg; D Buchen; J S Suh; D T Wong; S F Leibowitz
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Serotonergic responses in depressed patients with or without a history of alcohol use disorders and healthy controls.

Authors:  Leo Sher; Barbara H Stanley; Thomas B Cooper; Kevin M Malone; J John Mann; Maria A Oquendo
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-30       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.